Good news! Focusfreda has been granted a new US invention patent
Recently, the "STRAIN OF ENTEROBACTER FOR DEGRADING HYALURONIC ACID AND APPLICATION THEREOF“ jointly applied by Focusfreda and Jiangnan University was authorized by the United States Patent and Trademark Office (patent number: US11807847B2).
The patent relates to an enterobacter that degrades hyaluronic acid and its culture method and application, which has the ability to produce hyaluronidase efficiently, and has a wide application prospect in the fields of medicine and cosmetics. This technological breakthrough is of great significance and can be applied to the preparation of low molecular hyaluronic acid and oligomeric hyaluronic acid. This hyaluronidase has the advantages of high specificity to hyaluronic acid, good thermal stability, good PH stability, suitable for large-scale industrial production, and so on. It can replace the traditional and expensive hyaluronidase extracted from animal tissue.
Over the years, based on the industrial system, talent advantages and innovation resources, Focusfreda has continued to accelerate the organic integration of the industrial chain and innovation chain around the industry needs and development trends, and constantly improve the scientific research and innovation system from basic research, technological research, achievement transformation to industrial integration.
The authorization of the United States invention patent not only marks that this technology has been highly recognized internationally, but also marks that Focusfreda has made a breakthrough in technological innovation and international intellectual property layout.
In the future, we will continue to improve our R&D capabilities, strengthen the protection and application of intellectual property, inject new impetus into the vigorous development of China's sodium hyaluronate industry, and bring more healthy and beautiful choices to global consumers.